Hasbani Follows Up The Death Of Farah Kassab And Issues Two Decisions And Two Letters To The General

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:

In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,

Health Minister Ghassan Hasbani took the following actions:

The issuance of a decision on the prevention of surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
The issuance of a decision on the prevention of surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.

These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:

Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.

All

ATC	Name	B/G	Ingredients ↓	Dosage	Form	Price
C08DA01	ISOPTIN	B	Verapamil (HCl) - 80mg	80mg	Tablet, film coated	397,704 L.L
C08DA01	ISOPTIN SR	B	Verapamil (HCl) - 240mg	240mg	Tablet, film coated, prolonged release	1,128,821 L.L
R03BB04	INHALEX	G	Tiotropium bromide - 18mcg	18mcg	Capsule, inhalation	1,906,913 L.L
D05AA	ICHTAMMOL OINTMENT	G	Tars - 10%	10%	Ointment	90,869 L.L
D05AA	ICHTAMMOL OINTMENT	G	Tars - 10%	10%	Ointment	174,060 L.L
N02CC01	IMIGRAN	B	Sumatriptan (succinate) - 50mg	50mg	Tablet, film coated	378,964 L.L
N02CC01	IMIGRAN	B	Sumatriptan (succinate) - 100mg	100mg	Tablet, film coated	616,824 L.L
R01AX	ISOTONIC SODIUM CHLORIDE	G	Sodium chloride - 0.9%	0.9%	Solution	153,582 L.L
B05XA03	ISOTONIC SALINE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	188,772 L.L
B05XA03	ISOTONIC SALINE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	174,553 L.L
B05XA03	ISOTONIC SALINE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	167,780 L.L
B05XA03	ISOTONIC SALINE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	170,630 L.L
B05XA03	ISOTONIC SALINE	G	Sodium chloride - 0.9%	0.9%	Injectable solution	166,708 L.L
C10BA02	INEGY	G	Simvastatin - 40mg, Ezetimibe - 10mg		Tablet	4,484,594 L.L
C10BA02	INEGY	G	Simvastatin - 20mg, Ezetimibe - 10mg		Tablet	4,452,598 L.L
D06BA51	IALUGEN PLUS	B	Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 2mg/g		Cream	1,064,323 L.L
D06BA51	IALUGEN PLUS	B	Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 0.5mg/g		Gauze	1,463,444 L.L
R03AL02	IPRASAL VEM	G	Salbutamol (sulfate) - 2.5mg/2.5ml, Ipratropium bromide (monohydrate) - 0.5mg/2.5ml		Inhaltion solution with nebuliser	417,935 L.L
L01EA05	ICLUSIG	B	Ponatinib - 45mg	45mg	Tablet, film coated	207,092,651 L.L
L01EA05	ICLUSIG	B	Ponatinib - 15mg	15mg	Tablet, film coated	103,555,839 L.L
L04AX06	IMNOVID	B	Pomalidomide - 4mg	4mg	Capsule, hard	L.L
L04AX06	IMNOVID	B	Pomalidomide - 4mg	4mg	Capsule, hard	417,741,356 L.L
L04AX06	IMNOVID	B	Pomalidomide - 2mg	2mg	Capsule, hard	407,188,707 L.L
J07CA06	INFANRIX IPV + HIB	B	Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ≥40IU, Diphtheria toxoid (Prefilled syringe) - ≥30IU, H. Influenza type b polysaccharide(Vial) - 10mcg		Injectable dry powder+suspension	3,014,239 L.L
B02BD04	IMMUNINE	BioHuman	Plasma coagulation factor IX, human - 600IU	600IU	Injectable lyophilised powder for solution+diluent	20,506,214 L.L
M01AC01	INFLACAM	G	Piroxicam - 20mg/ml	20mg/ml	Injectable solution	193,513 L.L
M01AC01	INFLACAM	G	Piroxicam - 20mg/ml	20mg/ml	Injectable solution	190,826 L.L
A10BD09	INCRESYNC	B	Pioglitazone - 30mg, Alogliptin - 25mg		Tablet, film coated	3,897,143 L.L
A10BD09	INCRESYNC	B	Pioglitazone - 15mg, Alogliptin - 25mg		Tablet, film coated	3,897,143 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 75mg	75mg	Injectable suspension, prolonged release	15,240,102 L.L